IMUGENE CHART. TA only, page-1332

AFR article excerpt below today, questioning the high valuation could have something to do with the SP drop

One advantage of having a ridiculous 4.9 billion shares on issue is that you really can throw them around like confetti. Consider an ASX biotech named Imugene. It has no revenue or products and is at the clinical trial stage, but reached an incredible $2.3 billion market-cap based on a 47¢ share price on Wednesday. Imugene chief executive Leslie Chong sold 4.49 million shares after the May 18 announcement, raking in $1.65 million. Paul Jeffers Its chief executive Leslie Chong disclosed late on Tuesday that she sold 4.49 million shares on-market between May 19 and May 25 for cash proceeds of $1.65 million. The selling started a day after May 18 announcements promoting a licensing agreement with a US cancer research centre named City of Hope. Chong says the share sales were required to fund the exercise of 36.2 million share options between 4¢ and 4.5¢ at a total cost of $1.52 million to herself at the same time. Over the period she sold on-market the stock price increased a handy 38 per cent from a 33¢ close on May 18 to 45.5¢ close on May 25.Another director named Charles Walker sold 3.5 million shares on-market between May 18 to May 21 for cash proceeds of $1.24 million and didn’t exercise any options. If Walker had sold this time last year when shares closed at just 3.2¢ that pay day would have been just $112,000